RT Journal Article
SR Electronic
T1 First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005301
DO 10.1136/jitc-2022-005301
VO 11
IS 3
A1 Postel-Vinay, Sophie
A1 Lam, Vincent K
A1 Ros, Willeke
A1 Bauer, Todd M
A1 Hansen, Aaron R
A1 Cho, Daniel C
A1 Stephen Hodi, F
A1 Schellens, Jan H M
A1 Litton, Jennifer K
A1 Aspeslagh, Sandrine
A1 Autio, Karen A
A1 Opdam, Frans L
A1 McKean, Meredith
A1 Somaiah, Neeta
A1 Champiat, Stephane
A1 Altan, Mehmet
A1 Spreafico, Anna
A1 Rahma, Osama
A1 Paul, Elaine M
A1 Ahlers, Christoph M
A1 Zhou, Helen
A1 Struemper, Herbert
A1 Gorman, Shelby A
A1 Watmuff, Maura
A1 Yablonski, Kaitlin M
A1 Yanamandra, Niranjan
A1 Chisamore, Michael J
A1 Schmidt, Emmett V
A1 Hoos, Axel
A1 Marabelle, Aurelien
A1 Weber, Jeffrey S
A1 Heymach, John V
YR 2023
UL http://jitc.bmj.com/content/11/3/e005301.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.